By targeting the bradykinin-B2-receptor with novel small molecules, Pharvaris is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases.

In December 2023, Pharvaris announced positive top-line data from the CHAPTER-1 Phase II clinical study meeting its primary endpoint, with deucrictibant.